middle.news
EBR Systems Doubles Q4 Implants, Accelerates Clinical Trials and Revenue Growth
8:48am on Monday 12th of January, 2026 AEDT
•
Healthcare
Read Story
EBR Systems Doubles Q4 Implants, Accelerates Clinical Trials and Revenue Growth
8:48am on Monday 12th of January, 2026 AEDT
Key Points
WiSE System implants doubled in Q4 2025 to 18 cases
Preliminary Q4 revenue expected between US$870K and US$935K
Nine new purchase agreements signed, 11 physicians trained
WiSE-UP post-approval and TLC-AU feasibility studies commenced
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Ebr Systems (ASX:EBR)
OPEN ARTICLE